Infections Clinical Trial
— IRISOfficial title:
The IRIS Program: A Novel Pathway to Optimize Treatment of Injection-related Infections for People Who Inject Drugs in Hamilton, Ontario
People who inject drugs are at risk of injection-related infections, like abscesses or infective endocarditis. The Injection-Related InfectionS (IRIS) program hopes to improve treatment for participants by providing a low-barrier, one-stop shop model for people who inject drugs who experience injection-related infections to access more holistic and compassionate care. IRIS is a non-randomized clinical trial, meaning that it offers a specific program to eligible patients. This program offers care for substance use and infectious disease with additional peer support and systems navigation, if interested. The investigators anticipate enrolling 80 participants in the intervention and will follow participants throughout the infection treatment period (estimated 6-12 weeks). The investigators will collect information at the time of enrolment, at the 6-month mark, and monthly via electronic medical chart review. The investigators will use an interrupted time series analysis to evaluate the impact of the intervention on rates of treatment completion, emergency department visits, hospitalizations, and death, before versus after the intervention.
Status | Not yet recruiting |
Enrollment | 80 |
Est. completion date | December 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 105 Years |
Eligibility | Inclusion Criteria: - Age 16 or older - Able to provide informed consent - Presenting with a confirmed or suspected injection-related infection (including skin and soft tissue infections, osteomyelitis, infective endocarditis, Hepatitis C, HIV, etc) - History of injection drug use within 3 months of recruitment - Lives in Hamilton, Ontario Exclusion Criteria: - |
Country | Name | City | State |
---|---|---|---|
Canada | David Braley Health Science Centre | Hamilton | Ontario |
Canada | HAMSMaRT Clinic | Hamilton | Ontario |
Lead Sponsor | Collaborator |
---|---|
McMaster University | HAMSMaRT, Keeping Six, YWCA Hamilton |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of emergency department visits and hospital readmission | Within 30 days of initial hospital admission or program enrolment | ||
Secondary | Completion of intended course of treatment for the injection-related infection | Investigators will record whether or not participants have completed the intended course of treatment for their injection-related infection (e.g. completed course of antibiotics - YES or NO). | Within 6 months of initial hospital admission or program enrolment | |
Secondary | Number of hospital readmissions specifically for the infection that was the primary reason for program enrolment | Within 90-days of hospital discharge or program enrolment | ||
Secondary | Number of emergency department visits | Within 90-days of hospital discharge or program enrolment | ||
Secondary | Number of new initiations or record of continuation of substance use treatment | Within 90-days of hospital discharge or program enrolment | ||
Secondary | Mortality rates | Within 6-months of hospital discharge or program enrolment | ||
Secondary | Rates of program drop-out and reasons for discontinuation | Within 6-months of hospital discharge or program enrolment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06055777 -
Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts
|
Phase 1 | |
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Recruiting |
NCT05793983 -
S100A8/A9 and Innate Immunity in Liver Disease
|
||
Active, not recruiting |
NCT05963269 -
The Effect of the Game on Students' Intramuscular Injection Skills
|
N/A | |
Not yet recruiting |
NCT06026852 -
Validation of Betalactam ML Prediction Models - TDMAide
|
N/A | |
Not yet recruiting |
NCT02222779 -
Quantification of Transition Metals
|
N/A | |
Completed |
NCT01976234 -
Stored RBC Transfusion and Immonomodulation
|
N/A | |
Completed |
NCT02345135 -
Susceptibility to Infections in Ataxia Telangiectasia
|
N/A | |
Completed |
NCT01530763 -
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP)
|
Phase 2/Phase 3 | |
Completed |
NCT01158560 -
A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01176786 -
Reusable Versus Disposable Draping System in Breast Reconstruction Surgery
|
N/A | |
Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
Enrolling by invitation |
NCT06055712 -
Antibiotic Prophylaxis in Pediatric Open Fractures
|
Phase 4 | |
Not yet recruiting |
NCT06338345 -
Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients
|
N/A | |
Not yet recruiting |
NCT06402292 -
Surgical Treatment of Osteoarticular Infections Using Bioactive Bone Substitute
|
N/A | |
Recruiting |
NCT06002685 -
Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention
|
N/A | |
Completed |
NCT02802059 -
E. Coli Nissle 1917 - Suspension for Infection Prophylaxis
|
Phase 3 | |
Completed |
NCT05289674 -
The Effect of Lactoferrin in High Calorie Formula on IL-6 and IL10 in Children With Failure to Thrive and Infection
|
N/A | |
Recruiting |
NCT05770765 -
Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases
|
||
Completed |
NCT05389540 -
Rural South and Southeast Asia Household Health Survey
|